Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.57 |
| ▸ | EBP | Q15125 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814712 | 0.86 | ESR1 (0.75) | ESR1ESR2CYP26A1 | |
| SCHEMBL8386622 | 0.86 | ESR1 (0.75) | ESR1ESR2CYP26A1 | |
| SCHEMBL18845470 | 0.81 | ESR1 (0.60) | ESR1ESR2EBPSIGMAR1CYP26A1 | |
| SCHEMBL20234951 | 0.81 | ESR1 (0.57) | ESR1EBPSIGMAR1 | |
| SCHEMBL18815872 | 0.80 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL14289688 | 0.80 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL2817611 | 0.78 | ESR1 (0.86) | ESR1ESR2EBPSIGMAR1CYP26A1 | |
| SCHEMBL3652303 | 0.78 | ESR1 (0.79) | ESR1ESR2 | |
| SCHEMBL27256081 | 0.78 | S1PR1 (0.40) | ESR1ESR2CYP26A1 | |
| SCHEMBL27256083 | 0.77 | ESR1 (0.55) | ESR1ESR2EBPSIGMAR1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885EBP 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.